MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.19 1.71

Overview

Share price change

24h

Current

Min

1.18

Max

1.28

Key metrics

By Trading Economics

Income

206K

-60M

EPS

-0.28

Profit margin

272,450

Employees

226

EBITDA

-302K

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+644.07% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

2.2M

258M

Previous open

-0.52

Previous close

1.19

News Sentiment

By Acuity

28%

72%

60 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jul 2025, 17:03 UTC

Major Market Movers

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 Jul 2025, 15:18 UTC

Major Market Movers

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 Jul 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jul 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 Jul 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 Jul 2025, 21:01 UTC

Acquisitions, Mergers, Takeovers

AT&T and TPG Close DIRECTV Transaction

2 Jul 2025, 20:26 UTC

Earnings

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 Jul 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 Jul 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 Jul 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 Jul 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 Jul 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 Jul 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 Jul 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 Jul 2025, 17:05 UTC

Acquisitions, Mergers, Takeovers

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 Jul 2025, 17:04 UTC

Acquisitions, Mergers, Takeovers

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 Jul 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2 Jul 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 Jul 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 Jul 2025, 15:59 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 Jul 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 Jul 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2 Jul 2025, 15:00 UTC

Acquisitions, Mergers, Takeovers

Glencore: Merger of Viterra With Bunge Global Closed

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

644.07% upside

12 Months Forecast

Average 8.78 USD  644.07%

High 14 USD

Low 4 USD

Based on 13 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

60 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.